Edison Investment Research Limited: Polyphor (POLN): Balixafortide Phase III data coming soon
Objective response rate (ORR) data from the trial are expected in Q221 and could allow for an accelerated approval filing in the US.
- Objective response rate (ORR) data from the trial are expected in Q221 and could allow for an accelerated approval filing in the US.
- About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac.
- The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise.At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders.
- Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.